Pfizer Vfend Antifungal Has Broader Indication, Doses Than Merck’s Cancidas
Executive Summary
Pfizer's Vfend has a broader indication and more dosing options than Merck's Cancidas upon FDA approval of the Pfizer antifungal
You may also be interested in...
Pfizer Vfend approval
Pfizer's Vfend receives supplemental approval for treatment of esophageal candidiasis Nov. 14. Vfend (voriconazole) was initially approved for primary invasive aspergillosis therapy in May 2002 (1"The Pink Sheet" June 3, 2002, p. 10)...
Pfizer Vfend approval
Pfizer's Vfend receives supplemental approval for treatment of esophageal candidiasis Nov. 14. Vfend (voriconazole) was initially approved for primary invasive aspergillosis therapy in May 2002 (1"The Pink Sheet" June 3, 2002, p. 10)...
Pfizer Vfend Sets New Efficacy Standard In Invasive Aspergillosis, FDA Says
Pfizer's Vfend sets a "new standard" for non-inferiority trials in invasive aspergillosis, FDA says in review documents for the antifungal